Challenges and countermeasures in the treatment of luminal breast cancer
10.3760/cma.j.cn112152-20200302-00158
- VernacularTitle:Luminal型乳腺癌的治疗难点和应对策略
- Author:
Hai WANG
1
;
Xiyu LIU
;
Yizhou JIANG
;
Zhiming SHAO
Author Information
1. 复旦大学附属肿瘤医院乳腺外科 复旦大学上海医学院肿瘤学系，上海 200032
- Keywords:
Breast neoplasms, Luminal;
Endocrine resistance;
Late recurrence;
Target
- From:
Chinese Journal of Oncology
2020;42(3):192-196
- CountryChina
- Language:Chinese
-
Abstract:
Luminal breast cancer is the most common subtype of breast cancer, representing more than 60% of all breast cancers. Endocrine resistance and late recurrence are two challenges in the treatment of luminal breast cancer. To overcome endocrine resistance in multiple levels, high-dose-fulvestrant can inhibit estrogen-receptor (ER)-dependent pathways, while targeted drugs can block ER-independent pathways.To reduce the risk of late recurrence in luminal breast cancer, recurrence prediction model should be formed. For patients with high risk of late recurrence, extended endocrine therapy, combination of ovarian function suppression (OFS) or vascular endothelial growth factor (VEGF) inhibitor could be utilized. Based on the challenges of the treatment, scientific research achievements can be used in clinical practice, and finally optimize the clinical treatment strategy.
